2Karima R , Matsumoto S , Higashi H , et al. The molecular pathogene-sis of endotoxic shock and organ failure [ J ] . Molecular Medicine To- day , 1999,5(3) :123 -132.
2Motzkus D,Schulz-Maronde S,Heitland A,et al. The novel beta-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. FASEB J,2006,20(10) :1701-1702.
3Leslie DB, Vietzen PS, Lazaron V, et al. Comparison of endotoxin antagonism of linear and cyclized peptides derived from limulus antilipopolysaccharide factor. Surg Infect ( Larchmt ) , 2006,7 ( 1 ) : 45- 52.
4Coats SR, Pham TT, Bainbridge BW, et al. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize Escherichia coli lipopolysaccharide at the TLR4 signaling complex. J Immunol, 2005 , 175 (7) :4490-4498.
5Opal S M , Scannon P J , Vincent J L , et al . Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis , 1999 ,180 (5) :1584-1589
6Bryant CE,Owellette A,Lohmann K,et al. The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood. Vet Immunol Immunopathol,2007,116 (3-4) : 182-189.
7Mullarkey M, Rose JR, Bristol J, et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther, 2003,304(3) :1093-1102.
8Verbon A , Dekkers PE , ten Hove T , et al. IC14 , an anti-CD14 antibody , inhibits endotoxin2mediated symptoms and inflammatory responses in humans. J Immunol ,2001,166 (5) :3599-3605
9Genth-Zotz S,von Haehling S,Bolger AP,et al. The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure. Eur J Heart Fail, 2006,8(4) :366-372.
10Reinhart K,Gluck T, Ligtenberg J, et al. CD14 receptor occupancy in severe sepsis: results of a phase Ⅰ clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med, 2004,32(5) :1100-1108.
